Stakeholders say the Trump administration’s importation plan would complicate tracking drugs and create inventory headaches for pharmacists. FDA on Monday (Oct. 7) sent draft guidance to the Office of Management and Budget that will likely allow drug makers to avoid paying rebates by importing their own drugs and biologics with new National Drug Codes. Pharmacovigilance Having the same drugs moving through the supply chain with different drug codes could make it difficult to collect, monitoring and researching post-market reports,...